ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 654

Type I Interferon Induces the Depletion and Dysfunction of Endothelial Progenitor Cells in Gld. ApoE-/- C57BL/6 Mice

Linyu Geng1, Shiying Wang1, Xuebing Feng2 and Lingyun Sun2, 1The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: animal models and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose To study whether the accelerated atherosclerosis in SLE is mediated by type I interferon (IFN-I) through the regulation of endothelial progenitor cells (EPCs) in gld. ApoE-/- C57BL/6 mice under normal chow diet.

Methods The gld. ApoE-/- mice were generated through intercrossing and backcrossing of gld. and ApoE-/- mice on C57BL/6 background. At 20 weeks of age, female gld. ApoE-/- mice were injected with either saline vehicle, synthetic CPG-oligodeoxynucleiotides (CPG-ODN) IRS423 (TLR7/9 agonists) or IRS661 (TLR7 antagonists) twice a week. 4 weeks later, mice were euthanized. Quantitative PCR was applied to detect the mRNA expressions of IFN-I inducible genes. EPCs in peripheral blood and bone marrow were recognized as Sca-1+CD309+ cells by FACS. The capacities of EPC to differentiate into mature endothelial cells, to re-adherent and to form vascular-like structure were measured to determine EPC functions. To find out whether EPC function could be modulated by other cytokines, EPCs from 24 weeks old female gld. ApoE-/- mice were cultured in vitro in the presence of either IFN-α, IL-1β, TNF-α, IRS423 (1μM), IRS954 (1μM) or saline vehicle control for 24 hours.

Results gld. ApoE-/- C57BL/6 mice displayed both aggravated lupus-like disease and atherosclerosis under normal diet. Decreased percentage of peripheral blood and bone marrow EPCs, impaired EPC functions and increased atherosclerotic lesion area were observed in gld. ApoE-/- mice. IRS661 treatment inhibited the expressions of IFN-I inducible genes (including IRF7, MX1, OAS1, OAS2 and IFIT-2), while IRS423 promoted the expressions of these genes. The number of EPCs and the ability of EPC to form normal endothelial cells monolayer, to form cavity structure and to re-adherent in gld. ApoE-/- mice were restored after IRS661 treatment, and deteriorated after IRS423 treatment. In vitro experiments showed that only recombinant IFN-α could affect EPC functions, while other interventions including IL-1β, TNF-α, IRS423 and IRS661 did not have a direct impact on EPC regulation.

Conclusion IFN-I, activated through the upregulation of the TLR7/9 signaling, could induce the depletion and dysfunction of both peripheral and BM EPCs in gld. ApoE-/- C57BL/6 mice, thus may contribute to the development of atherosclerosis.


Disclosure:

L. Geng,
None;

S. Wang,
None;

X. Feng,
None;

L. Sun,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/type-i-interferon-induces-the-depletion-and-dysfunction-of-endothelial-progenitor-cells-in-gld-apoe-c57bl6-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology